RPH-104 is under clinical development by R-Pharm and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RPH-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RPH-104 overview

RPH-104 is under development for the treatment of idiopathic recurrent pericarditis, myocardial infarction, Schnitzler syndrome, adult-onset Still's disease (AOSD), familial mediterranean fever (FMF), acute respiratory distress syndrome and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through subcutaneous route. The drug candidate is a fusion protein that acts by targeting IL-1beta/IL-1F2-induced signaling. It was also under development for Behcet’s disease.

RPH-104 was under development for the treatment of gouty arthritis (gout)


R-Pharm overview

R-Pharm (R Pharm) is a pharmaceutical company. It carries out the production of medicines, active pharmaceutical ingredients, laboratory equipment and high-tech medical systems. The company’s pipeline products portfolio includes Nemonoxacin, narlaprevir, Cefilavancin, SCY 078, RPH-120 and Radotinib. R Pharm provides services such as production, commercialization, installation and maintenance of medical systems and staff training. The company offers products in the therapeutic areas of oncology, hematology, immune diseases, antibiotics, antivirals, neurology, cardiology, multiple sclerosis, hemophilia, Covid-19 and diabetes. It also carries out research and development of products and technologies in partnership with Russian and foreign institutes. The company supplies medicinal products and laboratory equipment for the hospitals, federal medical research centers, clinical hospitals, and regional curative and preventive care institutions. It has operations in Russia, the US, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan, Belarus and Germany. R-Pharm is headquartered in Moscow, Russia.

For a complete picture of RPH-104’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.